HBV Hepatitis B modeling-rAAV

Hepatitis B is a serious and debilitating human disease caused by hepatitis B virus (HBV) infection. HBV infection is species-specific with a narrow host range. Chimpanzees may be considered the most effective host for the study of HBV infection when considering HBV infection rate and maintenance. However, the study of HBV in chimpanzees is heavily limited due to multiple ethical considerations. Tree shrews may serve as an alternative animal model for HBV infection, yet several shortcomings including the low infection rate, infection maintenance time, stability and repeatability limit the utility of Tree Shrews for HBV research. Due to these limitation associated with non-human primate models for the study of HBV mice with a uniform genetic background are often considered the best choice for HBV infection studies.

PackGene’s AAV-HBV carries a 1.3×HBV full-length genome, and a mouse model of persistent HBV infection can be prepared by one-time tail vein injection of AAV-HBV. This approach has several advantages including simple preparation, high success rate, uniformity, stability, a well-characterized dose-effect relationship, and a wide application range. Furthermore, the HBV-AAV mouse model has been validated and used across a wide range of HBV drug evaluations and vaccine screenings.

In addition to the advantages listed above, use of the AAV-HBV mouse model can greatly shorten preparation time for in vivo hepatitis B infection therapy research and development. This, when paired with the model’s low cost, can help accelerate the development of hepatitis B drug research and treatment programs. PackGene’s AAV-HBV viral vectors provide long terms stable expression of hepatitis B antigen for the fast and safe modeling of HBV.

PackGene’s rAAV offers unparalleled safety compared to Lentivirus and Adenovirus, with minimal risk of genome integration, low immunogenicity, and high operational safety. It’s widely used for long-term gene expression, lasting over a decade in some cases, and its diverse serotypes enable organ-specific targeting, such as AAV8’s preference for liver research and its role in creating the AAV-HBV mouse model.

Features of HBV rAAV Vector

Highest Security

Compared with Lentivirus and Adenovirus, rAAV shows outstanding safety advantages including an low probability of genome integration, low immunogenicity, and high experimental operation safety.


Long-term Transduction

Over the past 20 years, rAAV has been commonly used as a tool for efficient and long-term gene expression in basic research and clinical gene therapy. For example, rAAV induced transgene expression in non-human primate muscle tissue can last for more than 10 years.


Organ Specificity

The capsid proteins of different AAV serotypes recognize different receptors on the cell surface, cell infection efficiency varies across tissues, indicating organ targeting specificity. AAV8 is frequently used in liver research and is therefore the serotype of choice for generation of the AAV-HBV mouse model.

Our Advantages

Low Empty Shell

AAV-HBV TEM detects empty shell rate is below 30%


Low Endotoxin

Low endotoxin levels with <10EU/ml – suitable for animal experiments.


AAV-HBV Mycoplasma Test Negative


High Purity Titer

≥1E+13GC/ml for AAV8-based qPCR genome copies/ml


Complete Quality Inspection Reports Are Provided

Catalog No. Promoter type?
(what promoter do we have for HBV?)
Genotype and serotype
AAV-D#2012 ssAAV-HBV-D,ayw HBV-D, serotype ayw (The AAV virus harbors the l.3XHBV genome, belonging to genotype D and serotype ayw. This strain is capable of generating HBV DNA, HBeAg, and HBsAg. Originally employed in cell models and transgenic animals, it has become extensively utilized in contemporary HBV research. It is suitable for both cell and animal experiments.)
AAV-C-10433 ssAAV-HBV-C,adr HBV-C, serotype adr (The AAV virus carries the 1.3XHBV genome, belonging to genotype C2 and serotype adr. It can produce HBV DNA, HBeAg, and HBsAg. The C-type HBV is a prevalent strain in mainland China, known for its strong pathogenicity, although its mechanism remains unclear. It should be given careful consideration in drug development. Suitable for both cell and animal experiments.)
AAV-C-542 ssAAV-HBV-B, adw HBV-B, serotype adw (The AAV virus harbors the 13XHBV genome, characterized by genotype B and serotype adw. It has the ability to produce HBV DNA, HBeAg, and HBsAg. Although the B-type HBV is also common in mainland China, its pathogenicity is comparatively weaker than that of the C-type. However, it still warrants attention in drug development. Suitable for both cell and animal experiments.)


50ul and 100ul specification are available.

Technical Details
Operation Requirements

In 1994, the safety of rAAV as a gene therapy vector was recognized by the FDA. AAV are classified as biological safety is Grade 1 (BSL-1), which is the same as that of plasmid DNA. It is nevertheless recommended to adhere to BSL-2 laboratory precautions with a ClassⅡ biological safety cabinet for use.

Storage Requirements

Store the virus at -80°C and place it on ice during operation.


Calculate your expected usage in advance and PackGene will aliquot your virus according to your pre-determined requirements. This can help avoid unnecessary thawing and re-freezing after receiving your AAVs since freeze thaw cycles influence virus viability. If aliquoting is required, it is recommended to use PCR tubes with siliconized inner walls, or special virus preservation tubes with low protein binding rates.


Thaw your virus aliquots in an ice bath immediately before use.


Dilute with PBS or PBS / 0.001% F-68 if needed.

Designing AAV-HBV Mouse Model

Individual differences between operators and regional mouse available may result in inter-lab differences in AAV-HBV transgene expression. We therefore strongly recommended that a gradient of 3 to 4 AAV-HBV volumes injection be tested before formal experiments are carried out. For example, we may recommend testing a total of three serial dilutions: 1E+11GC; 2E+11GC; 3E+11GC.

Case Study
Products: HBV8-B-AAV from PackGene Biotech
Injection Method: Tail Vein Injection
Targeting Site: Liver
Animal Model: C57BL/6
Journal: Nature Neuroscience, 2022 (IF=10.103)
Paper Title: A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy
DOI: https://doi.org/10.1016/j.antiviral.2022.105265
All mouse experiments were performed according to the guidelines of the Laboratory Animal Management Ethics Committee at Xiamen University. C57BL/6 mice were injected with HBV/adeno-associated virus (AAV) (HBV–B from PackGene Biotech, HBV-D from Five Plus Molecular Medicine Institute, China) via the caudal vein. HCAb treatment was conducted as previously described (Zhou et al., 2020).
More Study Cases of PackGene’s AAV Services, please click here

Contact Us

2. Contact us (page)

Related Services / Products

Off the Shelf AAV Products

We offer a wide catalogue of pre-made AAVs for a multitude of research needs.


AAV Packaging Services

Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.


AAV Analytical Services

We are one of the few vendors that can do ALL in-house.